检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:马慧敏[1] 袁霞[1] 黄运良[1] 林燕峰[1] 刘彩霞[1]
出 处:《现代肿瘤医学》2009年第7期1233-1235,共3页Journal of Modern Oncology
摘 要:目的:评价紫杉醇联合顺铂(DDP)、5-氟尿嘧啶(5-FU)(TPF方案)治疗晚期鼻咽癌的疗效和不良反应。方法:Ⅲ-Ⅳa期鼻咽癌患者98例随机分为紫杉醇+顺铂+5-氟尿嘧啶新辅助化疗联合同期放化疗(治疗组)及以5-氟尿嘧啶+顺铂组成的同期放化疗组(对照组)。新辅助化疗药用量:紫杉醇135mg/m2,d1,顺铂20mg/m2,d1-5,5-氟尿嘧啶750mg/m2,d1-5,每21天重复,治疗组所有病人均接受两个疗程TPF方案新辅助化疗。第2程新辅助化疗后14天即开始放疗。两组同期放疗相同。放疗采取6MVX线常规照射,鼻咽部总剂量约DT70Gy/49天,颈部预防剂量约DT50-55Gy/35-42天,治疗剂量约60-70Gy/42-49天。比较两组疗效及不良反应。结果:治疗组鼻咽及颈部肿瘤消失的平均剂量小于对照组(P<0.05);两组肿瘤临床全消率分别为87.8%与77.6%(P<0.01)。不良反应主要为粒细胞下降、脱发、口腔黏膜反应及胃肠道反应,均能耐受。结论:紫杉醇联合顺铂、5-氟尿嘧啶新辅助化疗治疗晚期鼻咽癌可提高肿瘤消失率,是治疗晚期鼻咽癌有效安全的方案。Objective :To evaluate efficacy and toxicity of paclitaxel and cisplatin ( DDP), 5 - fluorouracil (5 - FU) programme (TPF) to treat advanced nasopharyngeal cancer. Methods:Total of 98 Ⅲ - Ⅳ a stage nasopharyngeal cancer patients were randomly divided into paclitaxel ,cisplatin ,5 -fluorouracil programme + neoadjuvant chemotherapy + radiotherapy and chemotherapy (treatment group) and 5 -fluorouracil + cisplatin + same period radiotherapy and chemotherapy (control group). New adjuvant chemotherapy: paclitaxel 135 mg/m^2, d1, cisplatin 20mg/ m^2 ,d1 -5,5 - fluorouracil 750mg / m^2 ,d1 -5, repeated every 21 days. Radiotherapy :6 -MV conventional X -ray radiation,nasopharyngeal total dose was about DT 70Gy/49 days,around the neck prevent dose DT 50 - 55Gy/35 - 42 days, the dose was about 60 - 70 Gy/42 - 49 days. Results : For treatment group, the average dose was less than the control group ( P 〈 0.01 ) ; For two groups tamordisappearing rates were 87.8% : 77.6% (P 〈 0.01 ). Adverse reactions were decline in grain cells, hair loss, oral mucositis and gastrointestinal reaction. Conclusion:Paclitaxel and cisplatin,5 -fluorouracil (TPF) programme for advanced nasopharyngeal cancer is effective.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.222